Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

This study is to determine if Healthy Donor FMT (hdFMT) improves the body's ability to fight cancer in patients with relapsed/refractory PD-L1 Positive NSCLC.

Trial Details

NCT ID
NCT05669846
Phase
PHASE2
Sponsor
Diwakar Davar
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Healthy Donor Fecal Microbiota Transplant (hdFMT)
  • Pembrolizumab
Locations (sample)
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589

Key Eligibility Criteria

  • Male participants:
  • A male participant must agree to use a contraception as detailed per protocol of this protocol during the treatment period and for at least 120 day…
  • Female participants:
  • A female participant is eligible to participate if she is not pregnant per protocol, not breastfeeding, and at least one of the following condition…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →